Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
Pezaro C, de Bono J, Olmos D, Reid A, Seed G, Bianchini D, Omlin A, Cassidy A, Tunariu N, Mukherji D, Attard G. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer 2013; 109:325-31.
Jun 27, 2013Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
Jun 27, 2013Br J Cancer 2013; 109:325-31
Pezaro C, de Bono J S, Olmos D, Reid A H M, Seed G, Bianchini D, Omlin Aurelius, Cassidy A M, Tunariu N, Mukherji D, Attard G
Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
von Minckwitz G, Fehm T, Barinoff J, Rüdiger T, Erbstoesser E, Fasching P, Karn T, Müller V, Jackisch C, Huober J, Hilfrich J, Tesch H, Schmitt W, Loibl S, Müller B, Blohmer J, Sinn B, Eidtmann H, Eiermann W, Gerber B, Denkert C. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer. Clin Cancer Res 2013; 19:4521-31.
Jun 27, 2013Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
Jun 27, 2013Clin Cancer Res 2013; 19:4521-31
von Minckwitz Gunter, Fehm Tanja, Barinoff Jana, Rüdiger Thomas, Erbstoesser Erhard, Fasching Peter A, Karn Thomas, Müller Volkmar, Jackisch Christian, Huober Jens, Hilfrich Jörn, Tesch Hans, Schmitt Wolfgang D, Loibl Sibylle, Müller Berit M, Blohmer Jens U, Sinn Bruno V, Eidtmann Holger, Eiermann Wolfgang, Gerber Bernd, Denkert Carsten
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6:vi99-105.
Jun 27, 2013Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Jun 27, 2013Ann Oncol 2013; 24 Suppl 6:vi99-105
Früh M, De Ruysscher D, Popat S, Crinò L, Peters S, Felip E, ESMO Guidelines Working Group
Tobacco-related cancer mortality: projections for different geographical regions in Switzerland
Jürgens V, ess s, Phuleria H, Früh M, Schwenkglenks M, Frick H, Cerny T, Vounatsou P. Tobacco-related cancer mortality: projections for different geographical regions in Switzerland. Swiss Med Wkly 2013; 143:w13771.
Jun 25, 2013Tobacco-related cancer mortality: projections for different geographical regions in Switzerland
Jun 25, 2013Swiss Med Wkly 2013; 143:w13771
Jürgens Verena, ess silvia, Phuleria Harish C, Früh Martin, Schwenkglenks Matthias, Frick Harald, Cerny Thomas, Vounatsou Penelope
Secondary spinal anaplastic ependymoma ten years after treatment of Hodgkin’s disease
Hochstrasser A, Hundsberger T, Siano M. Secondary spinal anaplastic ependymoma ten years after treatment of Hodgkin’s disease. Schweiz. Krebsbulletin 2013; 2:175-178.
Jun 25, 2013Secondary spinal anaplastic ependymoma ten years after treatment of Hodgkin’s disease
Jun 25, 2013Schweiz. Krebsbulletin 2013; 2:175-178
Hochstrasser Andreas, Hundsberger Thomas, Siano Marco
Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications
Schmid S, Öhlschlegel C, Nagel W, Zeisel C, Müller J, Rothermundt C. Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications. Case Rep Oncol 2013; 6:331-8.
Jun 22, 2013Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications
Jun 22, 2013Case Rep Oncol 2013; 6:331-8
Schmid Sabine, Öhlschlegel Christian, Nagel Wolfgang, Zeisel Christoph, Müller Joachim, Rothermundt Christian
Thymoma with molecularly verified "conversion" to T lymphoblastic leukemia/lymphoma over 9 years
Ertel V, Früh M, Guenther A, Cerny T, Fretz C, Cogliatti S. Thymoma with molecularly verified "conversion" to T lymphoblastic leukemia/lymphoma over 9 years. Leuk Lymphoma 2013; 54:2765-8.
Jun 21, 2013Thymoma with molecularly verified "conversion" to T lymphoblastic leukemia/lymphoma over 9 years
Jun 21, 2013Leuk Lymphoma 2013; 54:2765-8
Ertel Vera, Früh Martin, Guenther Alexander, Cerny Thomas, Fretz Christian, Cogliatti Sergio
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lück H, Schuster T, Wollschläger K, Untch M, Thomssen C, Eidtmann H, Stickeler E, Richter B, Hubalek M, Jackisch C, Stähler A, Beckmann M, Heilmann V, Huober J, Schrader I, Loibl S, du Bois A, von Minckwitz G. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. Breast Cancer Res Treat 2013; 139:779-87.
Jun 15, 2013Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Jun 15, 2013Breast Cancer Res Treat 2013; 139:779-87
Lück Hans-Joachim, Schuster Tibor, Wollschläger Kerstin, Untch Michael, Thomssen Christoph, Eidtmann Holger, Stickeler Elmar, Richter Barbara, Hubalek Michael, Jackisch Christian, Stähler Ann, Beckmann Matthias, Heilmann Volker, Huober Jens, Schrader Iris, Loibl Sibylle, du Bois Andreas, von Minckwitz Gunter
Cancer survivors in Switzerland: a rapidly growing population to care for
Herrmann C, Cerny T, Savidan A, Vounatsou P, Konzelmann I, Bouchardy C, Frick H, ess s. Cancer survivors in Switzerland: a rapidly growing population to care for. BMC cancer 2013; 13:287.
Jun 14, 2013Cancer survivors in Switzerland: a rapidly growing population to care for
Jun 14, 2013BMC cancer 2013; 13:287
Herrmann Christian, Cerny Thomas, Savidan Anita, Vounatsou Penelope, Konzelmann Isabelle, Bouchardy Christine, Frick Harald, ess silvia
EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. Case Rep Oncol 2013; 6:316-9.
Jun 13, 2013EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report
Jun 13, 2013Case Rep Oncol 2013; 6:316-9
Diem Stefan, Früh Martin, Rodriguez Regulo, Liechti Peter, Rothermundt Christian
Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease
Hundsberger T, Rohrbach M, Kern L, Rösler K. Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol 2013; 260:2279-2285.
Jun 8, 2013Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease
Jun 8, 2013J Neurol 2013; 260:2279-2285
Hundsberger Thomas, Rohrbach Marianne, Kern Lukas, Rösler Kai M
EBV-assoziiertes, primäres B-Zell-Non-Hodgkin-Lymphom des ZNS (PCNSL) nach Lebertrans-plantation
Müller-Westermann J, Hollenstein M, Hundsberger T, Tettenborn B (2013). EBV-assoziiertes, primäres B-Zell-Non-Hodgkin-Lymphom des ZNS (PCNSL) nach Lebertrans-plantation.
Jun 8, 2013EBV-assoziiertes, primäres B-Zell-Non-Hodgkin-Lymphom des ZNS (PCNSL) nach Lebertrans-plantation
Jun 8, 201386. DGN-Jahreskongresses 2013
Müller-Westermann J, Hollenstein M, Hundsberger Thomas, Tettenborn Barbara
Zungenmyokymien- Drei Fälle, verschiedene Ätiologien
Leupold D, Schilg-Hafer L, Hundsberger T, Tettenborn B, Felbecker A (2013). Zungenmyokymien- Drei Fälle, verschiedene Ätiologien.
Jun 8, 2013Zungenmyokymien- Drei Fälle, verschiedene Ätiologien
Jun 8, 2013DGN Dresden Aktuelle Neurologie
Leupold Daniela, Schilg-Hafer Lenka, Hundsberger Thomas, Tettenborn Barbara, Felbecker Ansgar
Benefit and harms of new anti-cancer drugs
Vera-Badillo F, Al-Mubarak M, Templeton A, Amir E. Benefit and harms of new anti-cancer drugs. Curr Oncol Rep 2013; 15:270-5.
Jun 1, 2013Benefit and harms of new anti-cancer drugs
Jun 1, 2013Curr Oncol Rep 2013; 15:270-5
Vera-Badillo Francisco E, Al-Mubarak Mustafa, Templeton Arnoud, Amir Eitan
Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy
Bossi P, Siano M. Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy. JCO Journal of Clinical Oncology 2013; 31
May 25, 2013Identification of a gene expression profile associated with progression-free survival (PFS) in relapsed or metastatic (RM) head and neck squamous cell cancer (HNSCC) patients (pts) treated with first-line cetuximab and platinum therapy
May 25, 2013JCO Journal of Clinical Oncology 2013; 31
Bossi P, Siano Marco
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer 2013; 12:46.
May 24, 2013Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
May 24, 2013Mol Cancer 2013; 12:46
Kampa-Schittenhelm Kerstin, Heinrich Michael Charles, Akmut Figen, Rasp Katharina Henriette, Illing Barbara, Döhner Hartmut, Döhner Konstanze, Schittenhelm Marcus
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
Krönke J, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk R, Döhner H, Späth D, Kapp-Schwörer S, Bullinger L, Teleanu V, Tschürtz F, Gaidzik V, Kühn M, Rücker F, Holzmann K, Paschka P, Döhner K. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood 2013; 122:100-8.
May 23, 2013Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia
May 23, 2013Blood 2013; 122:100-8
Krönke Jan, Kindler Thomas, Schittenhelm Marcus, Krauter Jürgen, Ganser Arnold, Göhring Gudrun, Schlegelberger Brigitte, Schlenk Richard F, Döhner Hartmut, Späth Daniela, Kapp-Schwörer Silke, Bullinger Lars, Teleanu Veronica, Tschürtz Florian, Gaidzik Verena I, Kühn Michael W M, Rücker Frank G, Holzmann Karlheinz, Paschka Peter, Döhner Konstanze
Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
Schwitter M, Früh M, Schneider T, Kluckert J, Rodriguez R, Brutsche M. Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?. Oncology 2013; 2013:263-268.
May 14, 2013Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?
May 14, 2013Oncology 2013; 2013:263-268
Schwitter Michael, Früh Martin, Schneider Tino, Kluckert Jörg-Thomas, Rodriguez Regulo, Brutsche Martin
Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
Schwitter M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Früh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?. Case Rep Oncol 2013; 6:263-8.
May 14, 2013Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?
May 14, 2013Case Rep Oncol 2013; 6:263-8
Schwitter Michael, Rodriguez Regulo, Schneider Tino, Kluckert Thomas, Brutsche Martin, Früh Martin
FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma
Putora P, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. Respirology 2013; 18:734-5.
May 1, 2013FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma
May 1, 2013Respirology 2013; 18:734-5
Putora Paul Martin, Früh Martin, Müller Joachim